Clinical Trials Logo

Renal Angiomyolipoma clinical trials

View clinical trials related to Renal Angiomyolipoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06453642 Not yet recruiting - Clinical trials for Renal Cell Carcinoma

Evaluation of a Simple-Prep Controlled Embolic

GPX
Start date: June 2024
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in the USA, New Zealand, and Canada.

NCT ID: NCT05252585 Recruiting - Clinical trials for Renal Angiomyolipoma

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Start date: May 1, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this prospective study is to assess the safety and efficacy of everolimus in Taiwanese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) . Only patients who fulfil the local reimbursement criteria of everolimus for TSC-AML will be included in this study.

NCT ID: NCT03525834 Completed - Clinical trials for Renal Angiomyolipoma

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Start date: November 9, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study was to assess the safety and efficacy of everolimus (Afinitor®) in Chinese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC).

NCT ID: NCT02654340 Terminated - Clinical trials for Lymphangioleiomyomatosis

Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)

TuScCom
Start date: August 1, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal study to identify biomarker/s for Tuberous Sclerosis Complex and to explore the clinical robustness, specificity, and long´-term variability of these biomarker/s